Clinical Competition Candidate

OLUX E

Dermatology · Seborrheic dermatitis (scalp/body)

OLUX E carries product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 28 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

28months

to latest listed patent expiry (November 5, 2028)

Expiry attractiveness: 5/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (listed)

Patent count: 1

Complexity score: 1/5

Clinical competition

Score: 5/5

Active trials linked: 128

Phase 2/3 trials: 52

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: CLOBETASOL PROPIONATE

Applicant (NDA holder): PHARMOBEDIENT CONSULTING LLC

Confidence: High

Market context

Therapeutic area: Dermatology

Indication: Seborrheic dermatitis (scalp/body)

U.S. market size (est.)< $100M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.